FDA panel approves Ocular Therapeutix' ReSeal, with reservations

Fri, 09/20/2013 - 2:12pm
Mass Device

Ocular Therapeutix gets good and bad news from an FDA advisory panel that reviewed its ReSeal ophthalmic incision sealant.

FDA panel approves Ocular Therapeutix' ReSeal, with reservations

An FDA advisory panel voted yesterday that Ocular Therapeutix's ReSure topical hydrogel post-op sealant is safe, but split on questions of efficacy and whether the benefits of the treatment outweigh its risks.

The FDA's Ophthalmic Devices Panel voted 9-1, with 1 abstention, that the ReSure sealant is safe; 5-3, with 3 abstentions, that it is effective; and 5-1, with 5 abstentions, that its benefits outweigh its risks.

Ocular Therapeutix filed for PMA approval in February, based on a 488-patient clinical trial. The sealant's proposed indication is for temporary sealing of clear corneal incisions to prevent leakage of fluid after cataract or intraocular lens placement surgery. While the FDA is not bound by the recommendations of its advisory panels, the agency often follows their advice.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.